Visfatin: A potential biomarker for the early diagnosis and monitoring of acute coronary syndrome
Date
2019Author
YEŞİM GÜVENÇ DEMİRAĞCI;Serap ÇUHADAR;ÖZGÜR BAYTURAN;CEVVAL ULMAN;Gönül Dinç HORASAN;Ozan ÜTÜK;Mahmut ACAR
Metadata
Show full item recordAbstract
Objectives: Acute coronary syndrome (ACS) is a major cause of mortality and morbidity worldwide; thus, early diagnosis
is very important. The most common cause of ACS is the rupture of a vulnerable atherosclerotic plaque in the
coronary artery, an occurrence in which inflammation plays a key role. The aim of the present study was to investigate
visfatin as a proinflammatory biomarker in the early diagnosis and monitoring of ACS and to compare visfatin’s relationship
with troponin T, tumor necrosis factor-alpha (TNF-α), and creatine kinase-MB (CK-MB).
Methods: Sixty ACS patients and 30 healthy control subjects were enrolled in this study. One blood sample was drawn
from the control participants, and 3 were obtained from the ACS patients at intervals 0-6 hours (T0), 6-12 hours (T1),
and 12-24 (T2) hours from the start of chest pain. Serum visfatin, TNF-α, troponin T, and CK-MB levels were assessed.
Visfatin and TNF-α levels were assessed using enzyme-linked immunosorbent assay testing, troponin T was evaluated
using chemiluminescence, and CK-MB by enzymatic methods.
Results: Serum TNF-α, troponin T, and CK-MB levels in the T0 blood samples were statistically significantly higher in the
ACS patients compared with the controls (p=0.004, p<0.001, p<0.001, respectively). A significant positive correlation
was observed between visfatin and troponin T (r=0.290, p=0.007) in the T0 samples. Visfatin concentrations were lower
in the ACS group in the T0, T1 and T2 samples [4.01±6.23ng/mL, 1.80±3.47 ng/mL, and 1.72±2.67ng/mL, respectively;
p=0.005; T0 >(T1=T2)].
Conclusion: Visfatin had a significant positive correlation with troponin T. Visfatin did not demonstrate a rise and fall
pattern like the standard biomarkers in terms of monitoring the progress of ACS patients, as there was a significant
decrease after the first 6 hours. Although visfatin did not demonstrate superiority to troponin, its efficiency in a multimarker
panel merits further evaluation. The role of visfatin in the early phase of pathophysiological mechanisms requires
additional investigation.
URI
https://app.trdizin.gov.tr/publication/paper/detail/TXpNeE5qWTNOdz09http://hdl.handle.net/20.500.12481/3628
Collections
- TR - Dizin [3877]